샘플 요청 목록

 카트 문의
시장보고서
상품코드
1799106

세계의 천식 시장

Asthma Disease
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 177 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 천식 시장은 2030년까지 392억 달러에 이를 전망

2024년에 262억 달러로 추정되는 천식 세계 시장은 2024-2030년간 CAGR 7.0%로 성장하여 2030년에는 392억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 소아과는 CAGR 8.3%를 나타내고, 분석 기간 종료시에는 259억 달러에 이를 것으로 예측됩니다. 성인 부문의 성장률은 분석 기간중 CAGR 4.6%로 추정됩니다.

미국 시장은 71억 달러로 추정, 중국은 CAGR 11.2%로 성장 예측

미국의 천식 시장은 2024년에 71억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 83억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.4%와 6.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%를 보일 전망입니다.

세계의 천식 시장 - 주요 동향과 촉진요인 정리

천식에 대한 세계의 이해는 과학의 발전과 역학적 추세에 따라 어떻게 발전하고 있는가?

호흡기의 만성 염증성 질환인 천식은 전 세계적으로 가장 널리 퍼져 있는 복잡한 호흡기 질환 중 하나로, 모든 연령, 지역, 사회경제적 배경을 가진 사람들에게 영향을 미치고 있습니다. 전 세계적으로 3억 명 이상이 천식을 앓고 있는 것으로 추정되며, 이 질환은 공중 보건의 큰 관심사가 되고 있습니다. 최근 역학 및 면역학의 발전으로 천식은 만병통치약이 아니라 다양한 표현형과 종말형을 가진 이질적인 질환이라는 이해가 깊어지고 있습니다. 이러한 새로운 이해는 천식 진단 및 관리 방법을 재구성하고 맞춤 치료 전략의 필요성을 강조하고 있습니다. 유전적 소인이 주요 위험요인으로 작용하는 것은 변함없지만, 공해, 알레르겐, 직업적 자극물질, 도시화 등 환경적 영향이 질환의 발병과 악화에 관여할 가능성이 높아지고 있습니다. 특히 중저소득 국가에서 천식 유병률 증가는 생활양식의 변화, 산업화의 진전, 진단의 부족을 반영하고 있습니다. 천식의 부담은 천명, 호흡곤란, 기침 등의 신체적 증상뿐만 아니라 심리적 고통, 삶의 질 저하, 막대한 경제적 비용도 포함됩니다. 계절적 변동, 호흡기 감염, 비만이나 알레르기성 비염 등의 동반질환은 질환 관리를 더욱 복잡하게 만듭니다. 천식 유발인자, 면역 경로, 마이크로바이옴에 대한 연구의 발전은 혁신적인 진단 도구와 표적 치료의 길을 열어주고 있습니다. 천식은 관리 가능한 질환임에도 불구하고, 치료 접근성 격차, 일관성 없는 치료 순응도, 인식 부족으로 인해 예방 가능한 입원 및 사망으로 이어지고 있습니다. 천식 질환에 대한 과학적 통찰력이 높아짐에 따라, 천식이 전 세계적으로 미치는 영향을 효과적으로 줄이기 위해서는 여러 요인에 걸친 증거에 기반한 개별화된 접근이 필요하다는 것이 점점 더 분명해지고 있습니다.

천식 진단과 치료에 변화를 가져온 의료 기술 혁신은 어떤 것들이 있을까?

천식 관리는 의료 혁신과 디지털 기술의 통합을 통해 조기 진단, 지속적인 모니터링, 표적 치료를 강화하는 등 천식 관리가 크게 발전하고 있습니다. 흡입용 코르티코스테로이드와 기관지 확장제에만 의존하던 기존의 접근법은 생물학적 제제, 정밀의료, 디지털 건강의 발전에 힘입어 보다 정교한 치료 패러다임으로 변화하고 있습니다. IL-5, IL-4, IgE 등 특정 염증 경로를 표적으로 하는 단일클론항체 등 생물학적 제제를 이용한 치료는 기존 약물 치료에 반응하지 않는 중증 호산구성 천식 및 알레르기성 천식 환자 치료에 혁명을 일으키고 있습니다. 이러한 표적 치료는 악화율을 감소시키고, 폐 기능을 개선하며, 경구용 코르티코스테로이드 약물에 대한 의존도를 최소화하여 치료 결과를 개선하고 있습니다. 진단 측면에서는 호기 일산화질소 분획(FeNO) 검사 및 혈중 호산구 수와 같은 도구가 의사가 천식 표현형을 보다 정확하게 분류하고 그에 따라 치료법을 조정하는 데 도움을 주고 있습니다. 휴대용 폐활량계와 디지털 피크 유량계는 환자가 집에서 폐 기능을 모니터링할 수 있게 해주고, 자가 관리와 조기 개입을 지원하는 귀중한 실시간 데이터를 제공합니다. 모바일 앱과 센서가 내장된 흡입기의 등장으로 복약 순응도, 증상 패턴, 환경적 유발 요인을 추적할 수 있게 되어 임상의에게 실용적인 통찰력을 제공하면서 환자에게 힘을 실어줄 수 있게 되었습니다. 인공지능은 과거 데이터와 실제 증거를 바탕으로 악화를 예측하고 치료 계획을 개인화하기 위해 연구되고 있습니다. 모바일 기기와 동기화되는 스마트 흡입기는 천식 치료에서 가장 흔한 두 가지 문제를 해결하여 사용자에게 누출 및 잘못된 흡입 방법을 경고할 수 있습니다. 이러한 혁신은 보다 신속하고 환자 중심의 치료 모델을 구축하여 일상적인 치료와 정밀한 천식 관리의 격차를 해소하는 데 도움을 주고 있습니다.

사회경제적 요인, 생활습관의 변화, 환경적 압력이 천식 결과에 어떤 영향을 미치는가?

천식의 결과는 집단과 지역에 따라 크게 다른 사회경제적 결정요인, 환경적 노출, 진화하는 생활습관의 복잡한 상호작용에 의해 크게 영향을 받습니다. 도시에서는 교통 배기가스, 산업폐기물, 건설 분진 등으로 인한 대기오염에 노출되면 천식 발병 및 악화 위험이 크게 증가하며, 특히 소아 및 노인의 경우 천식 발병 및 악화 위험이 크게 증가합니다. 간접흡연, 곰팡이, 가정 내 알레르겐 등의 요인에 영향을 받는 실내공기질도 특히 주거환경이 열악한 저소득층의 경우 중요한 역할을 합니다. 앉아서 생활하는 습관 증가와 비만율 증가는 천식 조절 장애의 한 요인으로 대두되고 있으며, 대사 장애와 기도 염증 증가와 연관성이 있다는 연구 결과도 있습니다. 또한, 의료 서비스 접근성, 보험 적용, 건강 지식의 격차는 일관성 없는 진단, 치료 시작의 지연, 최적의 질병 통제에 기여하고 있습니다. 많은 신흥국에서 호흡기 전문 의료의 부재, 저렴한 약품의 부족, 진단 도구의 제한적인 가용성으로 인해 효과적인 관리를 방해하고 응급실 방문 및 입원 비율이 증가하고 있습니다. 만성질환을 둘러싼 문화적 신념과 편견도 치료 순응도와 치료 추구 행동에 영향을 미칠 수 있습니다. 기후 변화는 꽃가루가 날리는 시기의 변화, 산불 발생 빈도 증가, 폭염의 심화 등 호흡기 증상을 악화시킬 수 있는 복합적인 요소를 더욱 증가시키고 있습니다. 또한, 스트레스, 정신건강 문제, 우울증, 불안증과 같은 동반질환은 천식 증상을 악화시키고 환자의 예후에 악영향을 미치는 요인으로 인식되고 있습니다. 전 세계적으로 격차를 해소하고 천식 치료를 개선하기 위해서는 공공 정책, 교육, 지역사회 기반 개입을 통해 이러한 광범위한 건강 결정 요인을 해결하는 것이 필수적입니다.

천식 관리 시장의 지속적인 세계 성장의 원동력은 무엇인가?

천식 관리 시장의 성장은 질병 유병률 증가, 인식 개선, 치료 옵션의 발전, 디지털 헬스 솔루션의 사용 확대 등 여러 가지 복합적인 요인에 의해 주도되고 있습니다. 전 세계 인구 증가와 도시화 및 공해 증가로 인해 모든 연령대에서 천식 유병률과 진단율이 증가하고 있습니다. 사회적, 임상적 인식이 높아짐에 따라, 특히 조기 개입을 통해 질병의 진행을 바꿀 수 있는 소아 집단에서 보다 적극적인 스크리닝이 이루어지고 있습니다. 의약품의 혁신, 특히 생물학적 제제 및 복합 흡입제 분야에서는 치료 수단이 확대되어 보다 개인화되고 효과적인 개입이 가능해졌습니다. 가치 기반 건강관리로의 전환은 예방, 교육, 순응도에 초점을 맞춘 종합적인 천식 관리 프로그램의 채택을 촉진하고 있습니다. 정부와 의료 기관은 공중 보건 캠페인, 학교 기반 교육 프로그램, 천식 조절 및 자가 관리를 강조하는 가이드라인에 투자하고 있습니다. 첨단 치료법과 디지털 도구에 대한 보험 적용이 확대되면서 더 많은 환자층이 이용할 수 있게 되었습니다. 기술의 발전으로 환자, 의료 제공업체, 지불자를 연계된 생태계로 묶는 통합 케어 플랫폼의 개발이 가능해졌습니다. 특히 팬데믹 이후 원격 진료의 인기가 높아지면서 천식에 대한 원격 진료 및 재택 모니터링 솔루션의 채택이 가속화되고 있습니다. 이와 함께 천식의 유전적, 환경적 기반에 대한 연구를 통해 보다 정확한 예방 전략의 길이 열리고 있습니다. 이러한 다양한 촉진요인들이 총체적으로 세계 천식 시장의 지속적인 성장에 기여하고 있으며, 만성 호흡기 질환 환자의 예후와 삶의 질을 개선하기 위한 지속적인 혁신과 협력의 필요성을 강조하고 있습니다.

부문

연령층(소아과, 성인)

조사 대상 기업 예

  • AbbVie
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Circassia Pharmaceuticals
  • Cipla
  • GSK(GlaxoSmithKline)
  • Hikma Pharmaceuticals
  • Hyphens Pharma
  • Janssen Pharmaceuticals(J&J)
  • Mylan(now part of Viatris)
  • Novartis
  • Omega Pharma
  • Sanofi
  • Sandoz(Novartis)
  • Teva Pharmaceuticals
  • UCB
  • Vectura Group
  • Veracyte

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.09.03

Global Asthma Disease Market to Reach US$39.2 Billion by 2030

The global market for Asthma Disease estimated at US$26.2 Billion in the year 2024, is expected to reach US$39.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.9 Billion by the end of the analysis period. Growth in the Adults segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.1 Billion While China is Forecast to Grow at 11.2% CAGR

The Asthma Disease market in the U.S. is estimated at US$7.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Asthma Disease Market - Key Trends & Drivers Summarized

How Is the Global Understanding of Asthma Evolving with Scientific Advances and Epidemiological Trends?

Asthma, a chronic inflammatory disease of the airways, continues to be one of the most prevalent and complex respiratory disorders globally, affecting people of all ages, geographies, and socioeconomic backgrounds. With over 300 million individuals estimated to be living with asthma worldwide, the condition represents a major public health concern. Recent advances in epidemiology and immunology have deepened the understanding of asthma as a heterogeneous disease with multiple phenotypes and endotypes, rather than a one-size-fits-all condition. This new understanding has reshaped the way asthma is diagnosed and managed, highlighting the need for personalized treatment strategies. While genetic predisposition remains a major risk factor, environmental influences such as pollution, allergens, occupational irritants, and urbanization are increasingly implicated in disease onset and exacerbation. The rise in asthma prevalence, particularly in low- and middle-income countries, reflects changing lifestyles, increased industrialization, and underdiagnosis. Asthma’s burden is not limited to physical symptoms such as wheezing, breathlessness, and coughing, but also includes psychological distress, reduced quality of life, and significant economic costs. Seasonal variations, respiratory infections, and comorbidities such as obesity and allergic rhinitis further complicate disease management. The growing body of research on asthma triggers, immune pathways, and the microbiome is paving the way for innovative diagnostic tools and targeted therapies. Despite being a manageable disease, asthma still leads to preventable hospitalizations and deaths due to disparities in access to care, inconsistent adherence to treatment, and lack of awareness. As scientific insight into the disease deepens, it is becoming increasingly clear that asthma requires a multifactorial, evidence-based, and individualized approach to effectively reduce its global impact.

What Medical and Technological Innovations Are Transforming Asthma Diagnosis and Treatment?

The management of asthma has evolved significantly with the integration of medical innovation and digital technologies that enhance early diagnosis, continuous monitoring, and targeted treatment. Traditional approaches that rely solely on inhaled corticosteroids and bronchodilators are giving way to more sophisticated treatment paradigms driven by advances in biologics, precision medicine, and digital health. Biologic therapies such as monoclonal antibodies targeting specific inflammatory pathways like IL-5, IL-4, and IgE are revolutionizing treatment for patients with severe, eosinophilic, or allergic asthma who do not respond well to conventional medications. These targeted therapies are improving outcomes by reducing exacerbation rates, improving lung function, and minimizing dependence on oral corticosteroids. On the diagnostic front, tools like fractional exhaled nitric oxide (FeNO) testing and blood eosinophil counts are helping physicians more accurately classify asthma phenotypes and adjust therapies accordingly. Portable spirometry devices and digital peak flow meters allow patients to monitor lung function at home, providing valuable real-time data that supports self-management and early intervention. The rise of mobile apps and connected inhalers with embedded sensors enables tracking of medication adherence, symptom patterns, and environmental triggers, empowering patients while providing clinicians with actionable insights. Artificial intelligence is being explored to predict exacerbations and personalize treatment plans based on historical data and real-world evidence. Smart inhalers that sync with mobile devices can alert users to missed doses or incorrect inhaler techniques, addressing two of the most common challenges in asthma care. These innovations are creating a more responsive and patient-centered care model, helping to bridge the gap between routine treatment and precision-based asthma management.

How Do Socioeconomic Factors, Lifestyle Changes, and Environmental Pressures Impact Asthma Outcomes?

Asthma outcomes are profoundly influenced by a complex interplay of socioeconomic determinants, environmental exposures, and evolving lifestyle habits that vary widely across populations and regions. In urban areas, exposure to air pollution from traffic emissions, industrial waste, and construction dust significantly increases the risk of asthma onset and exacerbation, particularly in children and the elderly. Indoor air quality, influenced by factors such as secondhand smoke, mold, and household allergens, also plays a critical role, especially in low-income settings where housing conditions may be poor. The increasing adoption of sedentary lifestyles and rising rates of obesity are emerging as contributors to poor asthma control, with research indicating a link between metabolic disorders and heightened airway inflammation. In addition, disparities in healthcare access, insurance coverage, and health literacy contribute to inconsistent diagnosis, delayed treatment initiation, and suboptimal disease control. In many developing countries, the absence of specialized respiratory care, lack of affordable medications, and limited availability of diagnostic tools hinder effective management, leading to higher rates of emergency visits and hospitalizations. Cultural beliefs and stigma surrounding chronic illnesses may also affect treatment adherence and care-seeking behavior. Climate change is adding another layer of complexity by altering pollen seasons, increasing the frequency of wildfires, and intensifying heat waves, all of which can worsen respiratory symptoms. Moreover, stress, mental health issues, and comorbid conditions such as depression and anxiety are increasingly recognized as factors that exacerbate asthma symptoms and negatively impact patient outcomes. Addressing these broader determinants of health through public policy, education, and community-based interventions is essential to reducing disparities and improving asthma care globally.

What Is Driving the Continued Global Growth of the Asthma Disease Management Market?

The growth in the asthma disease management market is driven by several converging factors, including rising disease prevalence, increasing awareness, advances in therapeutic options, and expanding use of digital health solutions. A growing global population, coupled with increased urbanization and pollution, has led to higher incidence and diagnosis rates of asthma across all age groups. Heightened public and clinical awareness has resulted in more proactive screening, especially in pediatric populations where early intervention can alter disease progression. Pharmaceutical innovations, particularly in the area of biologics and combination inhalers, are expanding the treatment arsenal, allowing for more tailored and effective interventions. The shift toward value-based healthcare is encouraging the adoption of comprehensive asthma management programs that focus on prevention, education, and adherence. Governments and health organizations are investing in public health campaigns, school-based awareness programs, and guidelines that emphasize asthma control and self-management. Insurance coverage for advanced therapies and digital tools is also becoming more widespread, making them accessible to a broader patient population. Technological advancements are enabling the development of integrated care platforms that bring together patients, providers, and payers in a coordinated ecosystem. The increasing popularity of remote care, especially post-pandemic, has accelerated the adoption of telemedicine and home-monitoring solutions for asthma. In parallel, research into the genetic and environmental underpinnings of asthma continues to yield insights that could pave the way for even more precise and preventive strategies. These diverse drivers are collectively contributing to sustained growth in the global asthma market, highlighting the need for ongoing innovation and collaboration to improve outcomes and quality of life for individuals living with this chronic respiratory condition.

SCOPE OF STUDY:

The report analyzes the Asthma Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Age Group (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Circassia Pharmaceuticals
  • Cipla
  • GSK (GlaxoSmithKline)
  • Hikma Pharmaceuticals
  • Hyphens Pharma
  • Janssen Pharmaceuticals (J&J)
  • Mylan (now part of Viatris)
  • Novartis
  • Omega Pharma
  • Sanofi
  • Sandoz (Novartis)
  • Teva Pharmaceuticals
  • UCB
  • Vectura Group
  • Veracyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Asthma Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Asthma Spurs Sustained Demand for Long-Term Maintenance and Rescue Therapies
    • Here's How Urbanization, Pollution, and Climate Change Strengthen the Case for Expanded Asthma Diagnosis and Treatment Programs
    • Increased Focus on Early Detection and Prevention Throws the Spotlight on Biomarker-Based and Digital Screening Tools
    • Growing Awareness and Patient Education Initiatives Drive Higher Diagnosis Rates and Treatment Adherence
    • Here's the Story: Advances in Biologic Therapies Transform Management of Severe and Eosinophilic Asthma Subtypes
    • Development of Personalized Treatment Protocols Expands the Addressable Market for Genotype and Phenotype-Driven Asthma Care
    • Integration of Smart Inhalers and Digital Health Platforms Enables Remote Monitoring and Data-Driven Intervention
    • Expansion of Asthma Management Guidelines in Emerging Economies Fuels Growth in Inhaled Corticosteroids and Combination Inhalers
    • Here's the Story: AI and Predictive Analytics Enhance Risk Stratification and Exacerbation Forecasting in Chronic Asthma Patients
    • Pediatric and Geriatric Population Growth Supports Long-Term Market Opportunities Across Age Groups
    • Environmental Allergen Sensitization and Indoor Air Quality Issues Drive Demand for Comprehensive Management Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Asthma Disease Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • JAPAN
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • CHINA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • EUROPE
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • FRANCE
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • GERMANY
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • INDIA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • AFRICA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제